Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY
2023-503760-17-00Phase 2Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin in maturity-onset diabetes of the young type 3 (2 arms), sponsored by Steno Diabetes Center Copenhagen. Started Jun 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
maturity-onset diabetes of the young type 3
Beyond the preview
Go deeper on 2023-503760-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503760-17-00.